^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDH17-targeted antibody-drug conjugate

    Related drugs:
    Associations

    News

    Trials
    4d
    A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. (clinicaltrials.gov)
    P1/2, N=502, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1/2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    8d
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=405, Recruiting, Lepu Biopharma Co., Ltd. | Phase classification: P1/2 --> P1
    Phase classification
    9d
    A Phase 1 Study of HDM2017 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    New P1 trial
    14d
    A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=232, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial • First-in-human
    14d
    First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
    New P1/2 trial • First-in-human
    1m
    Study of CM518D1 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=434, Recruiting, Keymed Biosciences Co.Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    First-in-human Study of 7MW4911 in GI Cancer (clinicaltrials.gov)
    P1/2, N=200, Not yet recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
    New P1/2 trial • First-in-human
    2ms
    First in Human Study of TORL-3-600 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, TORL Biotherapeutics, LLC | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date • First-in-human
    4ms
    A Study of LM-350 in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, LaNova Medicines Limited
    New P1/2 trial
    5ms
    A Study of MRG007 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=336, Recruiting, Shanghai Miracogen Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    5ms
    A Study of MRG007 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=336, Not yet recruiting, Shanghai Miracogen Inc.
    New P1/2 trial
    5ms
    A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=220, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open